YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc. Before you buy NVIDIA: our AI model's stock picks are beating the mar…
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?…
CSL (ASX:CSL) has put kidney and liver disease firmly in focus, committing an upfront US$355 million to partner with Alentis Therapeutics on lixudebart and agreeing to fund upcoming Phase 2 and 3 trials. CSL's move on lixudebart lands afte…
CSL (CSLLY [https://seekingalpha.com/symbol/CSLLY]) and Alentis Therapeutics have entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver, and other diseases. Under the agreement, CSL (CSL [ht…
Investing.com-- CSL Ltd (ASX:CSL) shares rose on Monday after the Australian healthcare company said it had agreed to pay up to $1.6 billion to jointly develop and commercialise an experimental treatment for rare kidney and liver diseases.…
[Human kidney cross section. 3d illustration] Mohammed Haneefa Nizamudeen/iStock via Getty Images CSL (CSLLY [https://seekingalpha.com/symbol/CSLLY]) agreed to pay Alentis Therapeutics $355 million upfront as part of a global partnership t…
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today an…
HOLLY SPRINGS, N.C., Sept. 29, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing…
Sware gains 35 years of pharma technology leadership as life sciences organizations modernize validation for the AI era BOSTON, September 29, 2026--(BUSINESS WIRE)--Sware, Inc., the company behind the Res_Q, the AI-powered validation platf…
CSL (ASX:CSL) has secured a multi-year Advance Purchase Agreement extension with the UK government for its Aujemflu vaccine. The UK will be the first country to commercially launch CSL Seqirus' adjuvanted, trivalent cell-based influenza va…
CSL Canada has expanded public reimbursement for ANDEMBRY® (garadacimab), its once-monthly hereditary angioedema prophylaxis, across Quebec, Alberta and key federal programs, following strong Phase 3 trial data and a nomination for the 202…
Quebec became the first Canadian province to publicly reimburse ANDEMBRY®,1 followed by Alberta effective September 1, 2026, expanding provincial public access for eligible Canadians living with HAE.2 ANDEMBRY® is also covered through fede…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Bank of America on Thursday upgraded Haemonetics (HAE [https://seekingalpha.com/symbol/HAE]) to Buy from Neutral, citing a recent supply deal the blood management solutions provider si…
Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept. 10, 2026 /PRNewswire/ -- CSL Seqirus, a b…
Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ -- CSL Seqirus, a b…
This article first appeared on GuruFocus. A Deep Dive into CSL Ltd's Upcoming Dividend and Its Sustainability CSL Ltd (CSLLY) recently announced a total dividend of $0.41 per share, with the ex-dividend date set for 2026-09-10. This includ…
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the five…
[Inspecting capsules before production] Dejan Sarec/iStock via Getty Images U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cu…
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to…
* CSL press release [https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2026.pdf] (CSLLY [https://seekingalpha.com/symbol/CSLLY]): FY EPS of -$5.35 * Revenue of $15.8B. MORE ON CSL * CSL Limited (CSLLY) Q4 2026 Ea…
[Two coloured ropes knotted together] Richard Drury Shares of Haemonetics (HAE [https://seekingalpha.com/symbol/HAE]) added ~7% in the premarket on Tuesday after the blood management solutions provider disclosed a supply agreement with Aus…
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /P…
Investing.com -- Australian Prime Minister Anthony Albanese said he would raise Washington's new 12.5% tariff on Australian goods directly with U.S. President Donald Trump, Reuters reported. "We'll raise it at every level in the Australia-…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The Health Care Select Sector SPDR® Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]), which tracks the health car…
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal…
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal…
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal…
[Exterior view of the Sanofi headquarters building] HJBC * The European Commission has opened a formal antitrust investigation to assess whether Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) has breached EU competition rules by carryi…
[Red line graph with man] Jonathan Kitchen A number of large-cap stocks across sectors continue to carry persistent bearish quantitative signals in 2026, with several companies maintaining Seeking Alpha Strong Sell Quant Ratings for months…
CSL Canada is proud to recognize this important milestone of the first Canadian patient to receive HEMGENIX® (etranacogene dezaparvovec), the one-time gene therapy treatment for eligible patients living with hemophilia B, at London Health…
As the Australian market grapples with global uncertainties and fluctuating commodity prices, investors are increasingly seeking stability amidst the volatility. In such an environment, dividend stocks can offer a reliable income stream, m…
[FTC Sues To Block Drugmaker Amgen From Acquiring Rival] Mario Tama/Getty Images News Twenty people died in Japan after receiving Tavneos, a rare disorder therapy developed by Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), prompting…
This article first appeared on GuruFocus. CSL Ltd. (CMXHF) suffered its sharpest share-price drop on record after the Australian biotechnology company cut its full-year outlook, warned that its turnaround will take longer than expected, an…
(RTTNews) - Shares of CSL Limited (CMXHF.PK, CSL.AX, CSLLY) plunged around 18 percent in Australian trading after the biotech firm on Monday announced that it now expects an additional $5 billion impairment charge for fiscal 2026 and 2027,…